Viking Therapeutics Launches Phase 1 Study of VK3019 for Weight Loss
SAN DIEGO, June 24, 2026 Viking Therapeutics (NASDAQ: VKTX) announced the initiation of a Phase 1 clinical trial evaluating...
Obesity
Advertisement
Ascletis Receives FDA IND Clearance for ASC35 Obesity Trial
HONG KONG, June 23, 2026 Ascletis Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) has granted...
Cambrian Bio Reports Positive Phase 1b ATX-304 Data
NEW YORK, N.Y. | June 18, 2026 Cambrian Bio has presented positive Phase 1b clinical data for ATX-304, the...
LIR Shows Successful Needle-Free Delivery of GLP-1 Therapies
VANCOUVER, Canada, June 17, 2026 LIR Life Sciences Corp. announced the successful completion of its comparative preclinical animal study...
Engitix and GSK Partner to Advance Liver Fibrosis Drug Discovery
London, UK – June 8, 2026 Engitix Ltd., a biotechnology company specializing in extracellular matrix (ECM)-driven drug discovery, has...
Advertisements
Lilly’s Foundayo Outperforms Rivals in Landmark Diabetes Trials
INDIANAPOLIS, USA – June 8, 2026 Eli Lilly and Company has reported compelling new Phase 3 clinical data showing...
Boehringer’s Survodutide Delivers Major Metabolic Benefits
INGELHEIM, Germany – June 7, 2026 Boehringer Ingelheim has reported positive Phase III results for its investigational glucagon/GLP-1 dual...
Antag Therapeutics Reports Positive Phase 1 Results for AT7687 in Obesity
COPENHAGEN, Denmark, June 7, 2026 Antag Therapeutics presented positive Phase 1 clinical results and new preclinical findings for AT7687,...
Zealand Pharma Reports Positive Phase 2 Petrelintide Data in Obesity
COPENHAGEN, Denmark, June 5, 2026 Zealand Pharma announced new results from its Phase 2 ZUPREME-1 clinical trial evaluating petrelintide,...
Rivus Highlights RV-8451 Muscle-Preserving Obesity Data
CHARLOTTESVILLE, Va., and SOUTH SAN FRANCISCO, Calif., June 5, 2026 Rivus Pharmaceuticals announced new preclinical data for RV-8451, its...
Advertisement
